Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · IEX Real-Time Price · USD
143.31
-0.40 (-0.28%)
At close: Apr 26, 2024, 4:00 PM
146.71
+3.40 (2.37%)
After-hours: Apr 26, 2024, 7:42 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for ALNY stock have an average target of 215.4, with a low estimate of 150 and a high estimate of 395. The average target predicts an increase of 50.30% from the current stock price of 143.31.
Analyst Consensus: Buy
* Price targets were last updated on Mar 27, 2024.
Analyst Ratings
The average analyst rating for ALNY stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 5 | 5 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 6 | 7 | 7 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 19 | 19 | 20 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $234 | Buy | Maintains | $234 | +63.28% | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $395 | Strong Buy | Reiterates | $395 | +175.63% | Mar 5, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $165 → $150 | Hold | Maintains | $165 → $150 | +4.67% | Feb 23, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $235 | Buy | Reiterates | $235 | +63.98% | Feb 21, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $165 | Hold | Reiterates | $165 | +15.14% | Feb 20, 2024 |
Financial Forecast
Revenue This Year
1.88B
from 1.83B
Increased by 3.05%
Revenue Next Year
2.37B
from 1.88B
Increased by 25.90%
EPS This Year
-4.27
from -3.52
EPS Next Year
-1.80
from -4.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.1B | 3.1B | 4.9B | 7.2B | 8.9B |
| Avg | 1.9B | 2.4B | 3.2B | 4.2B | 5.6B |
| Low | 1.7B | 1.8B | 2.5B | 2.9B | 3.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.4% | 65.8% | 105.2% | 122.2% | 111.8% |
| Avg | 3.0% | 25.9% | 35.7% | 31.0% | 33.3% |
| Low | -4.5% | -2.6% | 7.5% | -11.1% | -26.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.01 | 1.43 | 10.35 | 24.26 | 27.96 |
| Avg | -4.27 | -1.80 | 2.32 | 9.50 | 16.55 |
| Low | -5.78 | -4.23 | -1.70 | 1.76 | 7.79 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 945.6% | 194.4% |
| Avg | - | - | - | 309.5% | 74.2% |
| Low | - | - | - | -24.0% | -18.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.